CDIX
Cardiff Lexington Corporation1.4200
-0.2900-17%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
57.37MP/E (TTM)
-Basic EPS (TTM)
-0.27Dividend Yield
0%Recent Filings
10-K
FY2025 results
Cardiff Lexington drove FY2025 revenue to $11.5M, up 39% y/y from $8.3M, fueled by more patient visits and higher-value surgeries at its 11 facilities running at 35% capacity. Gross margins expanded to 62% from 54% as costs rose slower than topline, yet massive $6.8M interest from its $17M line of credit—up 124% y/y—swamped operations into a $5.7M net loss before $238K discontinued ops gain. Cash burned $2.9M on ops amid 12-24 month A/R cycles at 41% realization. Q4 acceleration showed in sequential growth but liquidity stays razor-thin. Extended collections risk quarterly cash flow.
8-K
Removes Series N redemption rights
Cardiff Lexington amended its Series N Senior Convertible Preferred Stock designation on January 29, 2026, eliminating all redemption provisions—both optional company redemptions and holder-mandated ones in certain cases. Approved by requisite holders, the change was filed with Nevada's Secretary of State. Rights simplified. No financial impacts disclosed.
10-Q
Q3 FY2025 results
Cardiff Lexington's Q3 revenue rocketed 125.6% y/y to $3.1M from $1.4M, all from its Nova healthcare unit, driving gross profit to $1.9M (62.4% margin) versus $355K (26.2%) last year—operating income flipped to $643K profit from $585K loss. YTD revenue climbed 70.2% y/y to $8.8M with gross margin expanding to 62.1% from 46.8%, yet net loss widened to $2.8M from $2.4M on $4.6M interest expense, mainly line of credit fees; operating loss beat prior-year $526K loss. Cash dipped to $232K amid $2.5M ops burn, offset by $1.8M line draws—$15M total debt, $273K availability. Receivables ballooned to $21M on 42% settlement rate. Ongoing litigation poses risks.
10-Q
Q2 FY2025 results
Cardiff Lexington's Q2 FY2025 revenue surged 89.5% y/y to $2.8M, all from its healthcare segment, while gross profit jumped 149.8% to $1.7M with margins expanding to 60.8% from 46.1%, driven by a higher 43.18% settlement realization rate on gross billed charges. Operating income flipped to $610K from a $159K loss, though net loss widened to $1.2M due to $1.8M in interest expense on its line of credit. YTD revenue rose 50.4% to $5.7M with gross margins at 62.0%, but net loss hit $1.7M amid $2.8M interest costs; EPS of -$0.08 reconciles to 18.8M weighted shares. Cash dipped to $560K with negative FCF of $1.9M from operations, offset by $1.5M line draws, leaving $13.1M total debt and $2.3M unused credit; no M&A closed. Competition in orthopedic services remains a key risk.
IPO
Website
Employees
Sector
Industry
BKD
Brookdale Senior Living Inc.
10.49+0.19
CAH
Cardinal Health, Inc.
197.89-2.07
EHC
Encompass Health Corporation
108.01+0.42
HCA
HCA Healthcare, Inc.
469.79-7.19
NHC
National HealthCare Corporation
138.93-0.94
NUTX
Nutex Health Inc.
171.72-4.06
PACS
PACS Group, Inc.
34.20-0.55
PIII
P3 Health Partners Inc.
4.59-0.36
SNDA
Sonida Senior Living, Inc.
31.53-0.06
SRXH
SRX Health Solutions, Inc.
0.38+0.07